NK-cell depletion abolishes LIGHT-mediated tumor rejection
Primary challenge, mice, secondary challenge, and treatment* . | Tumor incidence, no./no. mice total(%)† . |
|---|---|
| 5 × 106 Ag104LdLIGHT | |
| C3B6F1 mice | |
| No secondary challenge | |
| None | 0/15 (0) |
| NK depletion (early)‡ | 6/6 (100) |
| CD8 depletion (early) | 6/6 (100) |
| LTβR-Ig (early) | 5/5 (100) |
| Anti-IFNγ (early) | 6/6 (100) |
| Control Ig (early) | 0/21 (0) |
| NK depletion (late)§ | 0/5 (0) |
| Anti-IFNγ (late) | 0/6 (0) |
| Control Ig (late) | 0/6 (0) |
| NK depletion (intratumor) | 6/6 (100) |
| Anti-IFNγ (intratumor) | 5/5 (100) |
| Control Ig (intratumor) | 0/5 (0) |
| Secondary challenge, 1 × 107 Ag104Ld | |
| NK depletion | 5/5 (100) |
| CD8 depletion | 5/5 (100) |
| Anti-IFNγ | 6/6 (100) |
| Control Ig | 0/6 (0) |
| 1 × 106 Ag104LdLIGHT | |
| Rag1 KO mice, no secondary challenge or treatment | 9/9 (100) |
| C3B6F1 mice, no secondary challenge or treatment | 0/9 (0) |
Primary challenge, mice, secondary challenge, and treatment* . | Tumor incidence, no./no. mice total(%)† . |
|---|---|
| 5 × 106 Ag104LdLIGHT | |
| C3B6F1 mice | |
| No secondary challenge | |
| None | 0/15 (0) |
| NK depletion (early)‡ | 6/6 (100) |
| CD8 depletion (early) | 6/6 (100) |
| LTβR-Ig (early) | 5/5 (100) |
| Anti-IFNγ (early) | 6/6 (100) |
| Control Ig (early) | 0/21 (0) |
| NK depletion (late)§ | 0/5 (0) |
| Anti-IFNγ (late) | 0/6 (0) |
| Control Ig (late) | 0/6 (0) |
| NK depletion (intratumor) | 6/6 (100) |
| Anti-IFNγ (intratumor) | 5/5 (100) |
| Control Ig (intratumor) | 0/5 (0) |
| Secondary challenge, 1 × 107 Ag104Ld | |
| NK depletion | 5/5 (100) |
| CD8 depletion | 5/5 (100) |
| Anti-IFNγ | 6/6 (100) |
| Control Ig | 0/6 (0) |
| 1 × 106 Ag104LdLIGHT | |
| Rag1 KO mice, no secondary challenge or treatment | 9/9 (100) |
| C3B6F1 mice, no secondary challenge or treatment | 0/9 (0) |
Number of tumor cells as indicated were injected subcutaneously into mice
The results were pooled from independent experiments
Treatment was done by administration of reagents intraperitoneally on days –3, 0, and 7 (day 0 is the day of primary or secondary tumor injection)
Treatment was done by administration of reagents intraperitoneally on days 14, 18, and 22